Zymeworks has completed its acquisition of Theravance Biopharma, expanding its commercial portfolio through YUPELRI profit-share revenue and additional royalty assets.
#Biotech #BiotechStocks #Pharma
Disclaimer: This is NOT a financial advice
@biotechstockdaily.bsky.social